Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
Zacks News
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark
by Zacks Equity Research
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
by Zacks Equity Research
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CORT) Outperforming Other Medical Stocks This Year?
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
New Strong Buy Stocks for May 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
by Zacks Equity Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Growth ETFs & Stocks Set to Flourish in Spring
by Sweta Killa
Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.
RedHill (RDHL) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Corcept Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock
by Zacks Equity Research
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
by Zacks Equity Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
What's in Store for Corcept (CORT) This Earnings Season?
by Zacks Equity Research
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
by Zacks Equity Research
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
by Zacks Equity Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
by Zacks Equity Research
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
New Strong Buy Stocks for January 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.